REFERENCES
- Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med.1997; 337: 898–909.
- Pascali E. Diagnosis and treatment of primary amyloidosis. Critic Rev Oncol Hemato. 1995; 19: 149–81.
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349: 583–96.
- Gertz MA, Li C-Y, Shirahama T et al. Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immu-noglobulin light chain). Arch Intern Med. 1988; 148: 929–33.
- Abraham RS, Katzmann JA, Clark RJ et al. Quantitative analysis of serum free light chains, a new marker for the diagnostic evalu-ation of primary systemic amyloidosis. Am J Clin Pathol. 2003; 119: 274–8.
- Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123i-labeled serum amyloid P component. N Engl J Med. 1990; 323: 508–13.
- Rysava R, Merta M, Spicka I et al. Current therapeutic possibi-lities in primary and secondary amyloidosis and our experience with 31 patients. Nephrol Dial Transplant; 2003, 18 (Suppl 5): v38–v40.
- Martha S, Vaishali S, David C et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amy-loidosis: an 8-year study. Ann Intern Med; 2004, 140:85–93.
- Pepys MB, Herbert J, Hutchinson WL et al. Targeted pharmaco-logical depletion of serum amyloid P component for treatment of human amyloidosis. Nature; 2002, 417:254–59.